Editorial - Annals of Cardiovascular and Thoracic Surgery (2019) Volume 2, Issue 3

8th Annual Congress on Cardiology and Cardiac Surgery, June 15-16, 2020 at Edinburgh, Scotland

Emeritus Professor, University of Minnesota, USA

Corresponding Author:

Gundu H.R. Rao
Emeritus Professor, University of Minnesota, USA
Email: gundurao9@gmail.com

According to new technical market research report, cardiovascular surgical devices were valued $29.7 billion in 2012 and the market growth has been increased up to $31.7 billion in 2013. BCC Research projects expected the market growth to nearly $47.2 billion by 2018 and register a five year compound annual growth rate (CAGR) of 8.3% from 2013 to 2018.

Cardiovascular disease is the leading cause of death for both men and women in the United States, as well as in many other countries around the world. The American Heart Association estimates that 83.6 million American adults, or more than one in three, have one or more types of cardiovascular disease. Indeed, more Americans die of heart disease than of the combination of all cancers and AIDS.

In 2010, over $7.5 million inpatient cardiovascular operations were performed in the United States alone. During that year, the total inpatient hospital cost for cardiovascular disease was estimated to be $71.2 billion about one quarter to the total cost of U.S. inpatient hospital care. The American Heart Association estimates that the total direct medical cost associated with cardiovascular disease in the U.S. has increased from an estimated $312.6 million in 2009 to almost $1.5 trillion, by 2030.

Cardiovascular Diseases (CVDs) comprise disorders and conditions related to circulatory system which include heart and vascular system. The global cardiovascular drugs market is anticipated to reach the value of approximately US$ 91.0 Bn by 2025. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel expansion of the global cardiovascular drugs market from 2017 to 2025.

Cardiovascular diseases are one of the leading causes of death worldwide. According to American Heart Association, it is estimated that cardiovascular disease is likely to increase to 45% by 2035. Sedentary lifestyle, changing dietary habits and surge in associated risk factors are likely to increase the number of patients with cardiovascular diseases. According to the Centers for Disease Control and Prevention (CDC) of the U.S., high blood pressure, high cholesterol, and smoking are key risk factors for heart disease. About half of the population of the U.S. (47%) have at least one of these three risk factors. To treat the diseases, key players are investing in to develop new drugs with better efficacy and less side effects.

The global cardiac biomarker diagnostic test kits market is expected to be worth US$ 2,540.8 Mn in 2028, and is projected to increase at a CAGR of 5.1% through 2028. North America is expected to be a dominant market, which accounted for US$ 522.5 Mn in 2017, and is expected to grow at a CAGR of 4.3%. North America has been the dominant regional market for heart diagnostics with a share of approximately 47% of the overall heart diagnostics market in terms of revenue in 2016, followed by Europe which accounted for around 38% share in the market and then by Asia accounting for 15% share.

Scope and Importance:

A prospective survey of patients with Valvular Heart Disease (VHD):

Coronary angiography was used in 85.2% of patients before intervention.

The Euro Heart Survey (EHS) programme has been initiated order to provide quantitative information on cardiovascular disease.

To prevent the incidence of cardiovascular (CV) disease, by implementing strategies to reduce the burden of CV risk factors and incidence of CV disease and

Develop appropriate models for healthy CV lifestyle.

The global cardiovascular therapeutics market continues to see rapid innovation with new drugs and devices entering the market. According to our cardiovascular market research experts, diabetes is one of the major factors leading to the current cardiovascular disease epidemic. The growing prevalence of chronic diseases such as diabetes is the major factor leading to the growth of the heart failure market. Due to the potential breakthrough of newly approved drugs entering the market, heart failure market size is expected to grow in the coming years.

Cardiovascular Drugs Market:

Major players in the global Cardiovascular drugs market include Merck & Co, Sanofi S.A, Pfizer Inc, Bristol-Myers Squibb Company, Novartis AG. The cardiovascular drugs market expected to reach a value of nearly $86.67 billion by 2022, significantly growing at a CAGR of 1.2% during the forecast period. The growth in the Cardiovascular drugs market is due to increase in aging population, increase in the prevalence of cardiovascular diseases and availability of more generic drugs that reduce the cost of treatment. Among the drugs used to treat cardiovascular diseases, the heart failure drugs market is one in particular expected to witness strong growth through 2022 due to the growing prevalence of chronic diseases such as diabetes. The global hypertension drugs market will post an impressive market value of USD 32 billion by the end of 2020. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60.

Regards,
Jennifer Park
Program Manager| Diabetes Summit 2020
Email: diabetessummit@alliedforums.org
Phone: (44) 2037691755
Whatsapp: +441785508016